ASX Announcement Independent Data Monitoring Committee to Review Phase 3 Clinical Trial Data of Recce’s Topical Gel for Diabetic Foot Ulcer Infections Highlights: • Review of the blinded data indicates strong efficacy across the study population ® • RECCE 327 Gel (R327G) continues to...
Independent Review of Indonesian Phase 3 R327G Trial Data
Filed with ASX ·
6ix is reading this filing.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Amendments to Debt Facility with Avenue Capital Group
- Appendix 4E and FY26 Annual Report
- HREC Approves Comparator Study for Pivotal Phase 3 DFI
- Vietnamese Patent Granted for RECCE Anti-Infectives
- AUD $3.7M Income Tax Refund Received
Later from Recce Pharmaceuticals
All Recce Pharmaceuticals news releasesFollow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals